AZ’s lung drug gets fast development in EU and US

Regulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing lower respiratory tract infection caused by respiratory syncytial virus (RSV) in very young babies.